IPSEN Group Follow / Connect - Business Profile & Social Media Wall / Press Room - Pharma / BioTech / Nutrition

IPSEN Group Company Profile & Social Media Wall Press Room - Press Releases

Ipsen is a global specialty-driven pharmaceutical group committed to discovering new solutions for targeted debilitating diseases and improving quality of life for patients.

	Company Name:	IPSEN Group
	Trading Symbol(s):	[Euronext: IPN; ADR: IPSEY]
	Contact:	Press Office - IPSEN.com
	Address:	Confidential
	City:	Boulogne Billancourt
	Zip code:	92100
	STATE / Prov.:	Hauts-de-Seine
	Country:	France
	Primary Industry:	Pharma / BioTech / Nutrition
	PR Agency:	No

Your Company Advertising Here!
Showing along with this industry
- Learn more...

Latest Articles:
Ipsen’s Kayfanda® (odevixibat) Approved in European Union for Cholestatic Pruritus in Alagille Syndrome, A Rare Liver Disease - [ Pharma / BioTech / Nutrition ]
Ipsen’s Iqirvo® Receives U.S. FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary Cholangitis - [ Pharma / BioTech / Nutrition ]
Ipsen Presents Long-term Elafibranor Efficacy and Itch-related Quality of Life Data in Patients with Primary Biliary Cholangitis - [ Pharma / BioTech / Nutrition ]
Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases - [ Pharma / BioTech / Nutrition ]
Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA - [ Pharma / BioTech / Nutrition ]
Ipsen Updates on E.U. Marketing Authorisation Application for Odevixibat in Alagille Syndrome - [ Pharma / BioTech / Nutrition ]
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib - [ Pharma / BioTech / Nutrition ]
US FDA Approves Ipsen’s Sohonos™ (palovarotene) Capsules, the First and Only Treatment for People with Fibrodysplasia Ossificans Progressiva - [ Pharma / BioTech / Nutrition ]
Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP - [ Pharma / BioTech / Nutrition ]
U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome - [ Pharma / BioTech / Nutrition ]
Ipsen to Present New Bylvay® (odevixibat) Data At ESPGHAN Congress, Showcasing Commitment to Furthering Treatment for Rare Cholestatic Liver Diseases - [ Pharma / BioTech / Nutrition ]
Ipsen, Université de Montréal and IRICoR Broaden Existing Oncology Partnership, with an Exclusive License Agreement & Two New Discovery-stage Programs - [ Pharma / BioTech / Nutrition ]
Cabometyx® in Combination with Nivolumab Shows Durable Survival Benefits At Over Three-years’ Follow-up in First-line Advanced Renal Cell Carcinoma - [ Pharma / BioTech / Nutrition ]
Ipsen Receives CHMP Negative Opinion for Palovarotene as A Treatment for Fibrodysplasia Ossificans Progressiva in E.U - [ Pharma / BioTech / Nutrition ]
Ipsen Presents Positive Results from the Pivotal Phase III NAPOLI 3 Trial Evaluating An Investigational Regimen of Onivyde® - [ Pharma / BioTech / Nutrition ]
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease with Treatments for Several Pediatric Liver Diseases - [ Pharma / BioTech / Nutrition ]
Ipsen Demonstrates Commitment to Innovation in Neuroscience At 12th World Congress for Neurorehabilitation (WCNR) - [ Pharma / BioTech / Nutrition ]
Ipsen’s Global Natural History Study of Fibrodysplasia Ossificans Progressiva Shows Debilitating Impact of the Disease Over An Individual’s Lifetime - [ Pharma / BioTech / Nutrition ]
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer - [ Pharma / BioTech / Nutrition ]
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-oncology Candidates from Marengo’s STAR Platform - [ Pharma / BioTech / Nutrition ]
Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology - [ Pharma / BioTech / Nutrition ]
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults - [ Pharma / BioTech / Nutrition ]
European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer - [ Pharma / BioTech / Nutrition ]
Ipsen Announces Investment in New State-of-the-art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) - [ Pharma / BioTech / Nutrition ]
Health Canada Approves Ipsen’s Sohonos (Palovarotene Capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva - [ Pharma / BioTech / Nutrition ]

Next Page »

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business

ó See your Ad Here! ó

PREMIUM Members

ó See your Logo Here! ó